menu
    • menu
    [{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"CND106","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"","sponsorNew":"Candid Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Candid Therapeutics","amount2":1,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":1,"dosageForm":"","sponsorNew":"Candid Therapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Candid Therapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Candid Therapeutics","amount2":0.32000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Candid Therapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Candid Therapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Candid Therapeutics","amount2":0.93000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.93000000000000005,"dosageForm":"","sponsorNew":"Candid Therapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Candid Therapeutics \/ Candid Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Candid Therapeutics

    Menu

    Candid Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Candid Therapeutics

    U.S.A arrow
    Battery Seminar
    Not Confirmed

    Candid Therapeutics

    U.S.A arrow
    Battery Seminar
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Immunology

    Study Phase : Preclinical

    Recipient : WuXi Biologics

    Deal Size : $925.0 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Candid Steps up TCE Deal Momentum with $925M WuXi Partnership

    Details : Under the agreement, Candid will have exclusive global rights to a tri-specific T-cell Engager discovered by the WuXi Biologics platform for treating autoimmune and inflammatory diseases.

    Product Name : Undisclosed

    Product Type : Antibody

    Upfront Cash : Undisclosed

    January 06, 2025

    Lead Product(s) : Undisclosed

    Therapeutic Area : Immunology

    Highest Development Status : Preclinical

    Recipient : WuXi Biologics

    Deal Size : $925.0 million

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Candid Therapeutics

    U.S.A arrow
    Battery Seminar
    Not Confirmed

    Candid Therapeutics

    U.S.A arrow
    Battery Seminar
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Antibody

    Therapeutic Area : Immunology

    Study Phase : Discovery

    Recipient : EpimAb Biotherapeutics

    Deal Size : $1,000.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Candid, EpimAb Collaborate on T-Cell Engagers for Autoimmune Disease Treatments

    Details : The companies have entered a strategic research collaboration to discover and develop novel T-cell Engager program candidates for various autoimmune indications.

    Product Name : Undisclosed

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    December 16, 2024

    Lead Product(s) : Antibody

    Therapeutic Area : Immunology

    Highest Development Status : Discovery

    Recipient : EpimAb Biotherapeutics

    Deal Size : $1,000.0 million

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Candid Therapeutics

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Candid Therapeutics

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Antibody

    Therapeutic Area : Immunology

    Study Phase : Discovery Platform

    Recipient : Nona Biosciences

    Deal Size : $320.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Nona Biosciences, Candid Collaborate on Next-Gen T-Cell Engager Discovery Projects

    Details : Nona's collaboration with Candid aims to advance the discovery of next-generation TCEs (T-cell engagers) focused on treating autoimmune diseases.

    Product Name : Undisclosed

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    December 16, 2024

    Lead Product(s) : Antibody

    Therapeutic Area : Immunology

    Highest Development Status : Discovery Platform

    Recipient : Nona Biosciences

    Deal Size : $320.0 million

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Candid Therapeutics

    U.S.A arrow
    Battery Seminar
    Not Confirmed

    Candid Therapeutics

    U.S.A arrow
    Battery Seminar
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Immunology

    Study Phase : Discovery

    Recipient : AB Studio

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Candid and Ab Studio Collaborate on T Cell Engagers for Autoimmune Disorders

    Details : The companies entered a strategic research collaboration to discover and develop novel T Cell Engager program candidates for various autoimmune indications.

    Product Name : Undisclosed

    Product Type :

    Upfront Cash : Undisclosed

    December 16, 2024

    Lead Product(s) : Undisclosed

    Therapeutic Area : Immunology

    Highest Development Status : Discovery

    Recipient : AB Studio

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Candid Therapeutics

    U.S.A arrow
    DCAT Week
    Not Confirmed

    Candid Therapeutics

    U.S.A arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CND106

    Therapeutic Area : Immunology

    Study Phase : Phase I

    Sponsor : Venrock Healthcare Capital Partners

    Deal Size : $370.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Candid Therapeutics Raises $370M to Evaluate Autoimmune Therapies Clinically

    Details : CND106 is a BCMAxCD3 bispecific antibody designed to target and eliminate later stage B-cells which are responsible for producing harmful autoantibodies.

    Product Name : CND106

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    September 09, 2024

    Lead Product(s) : CND106

    Therapeutic Area : Immunology

    Highest Development Status : Phase I

    Sponsor : Venrock Healthcare Capital Partners

    Deal Size : $370.0 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth